AG˹ٷ

STOCK TITAN

[6-K] Pharvaris N.V. Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Labcorp Holdings Inc. (NYSE: LH) filed a Form 8-K under Item 7.01 (Regulation FD) to disclose that its Board of Directors has declared a cash dividend of $0.72 per common share. The dividend will be payable on September 11, 2025 to shareholders of record at the close of business on August 28, 2025. No other financial metrics, strategic initiatives, or transactional details were provided in this filing. The company furnished the related press release as Exhibit 99.1 and included standard Exhibit 104 (Inline XBRL cover data). This disclosure signals continued capital returns to shareholders and may be relevant for income-oriented investors.

Labcorp Holdings Inc. (NYSE: LH) ha presentato un Modulo 8-K ai sensi dell'Articolo 7.01 (Regolamento FD) per comunicare che il suo Consiglio di Amministrazione ha dichiarato un dividendo in contanti di 0,72 dollari per azione ordinaria. Il dividendo sarà pagabile l'11 settembre 2025 agli azionisti registrati alla chiusura delle attività del 28 agosto 2025. Non sono stati forniti altri dati finanziari, iniziative strategiche o dettagli sulle transazioni in questa comunicazione. La società ha allegato il comunicato stampa correlato come Allegato 99.1 e ha incluso il consueto Allegato 104 (dati Inline XBRL). Questa comunicazione indica un continuo ritorno di capitale agli azionisti e potrebbe essere rilevante per gli investitori orientati al reddito.

Labcorp Holdings Inc. (NYSE: LH) presentó un Formulario 8-K bajo el Ítem 7.01 (Regulación FD) para informar que su Junta Directiva ha declarado un dividendo en efectivo de 0,72 dólares por acción común. El dividendo será pagadero el 11 de septiembre de 2025 a los accionistas registrados al cierre del negocio el 28 de agosto de 2025. No se proporcionaron otros datos financieros, iniciativas estratégicas ni detalles de transacciones en esta presentación. La compañía adjuntó el comunicado de prensa correspondiente como Anexo 99.1 e incluyó el Anexo 104 estándar (datos Inline XBRL). Esta divulgación indica una continuidad en la devolución de capital a los accionistas y puede ser relevante para inversores enfocados en ingresos.

Labcorp Holdings Inc. (NYSE: LH)� 항목 7.01(규정 FD)� 따라 Form 8-K� 제출하여 이사회가 보통� 1주당 0.72달러� 현금 배당� 선언했다� 공시했습니다. 배당금은 2025� 9� 11일에 지�되며, 2025� 8� 28� 영업 종료 시점� 주주명부� 등재� 주주에게 지급됩니다. � 공시에서� 다른 재무 지�, 전략� 계획, 거래 세부사항은 제공되지 않았습니�. 회사� 관� 보도자료� 전시� 99.1� 제출했으� 표준 전시� 104(인라� XBRL 표지 데이�)� 포함했습니다. 이번 공시� 주주� 대� 지속적� 자본 환원� 의미하며, 수익 지� 투자자에� 중요� � 있습니다.

Labcorp Holdings Inc. (NYSE: LH) a déposé un formulaire 8-K en vertu de l'article 7.01 (Règlement FD) pour annoncer que son conseil d'administration a déclaré un dividende en espèces de 0,72 $ par action ordinaire. Le dividende sera payable le 11 septembre 2025 aux actionnaires inscrits à la clôture des opérations du 28 août 2025. Aucun autre indicateur financier, initiative stratégique ou détail transactionnel n’a été fourni dans ce dépôt. La société a joint le communiqué de presse associé en tant qu’Exhibit 99.1 et inclus l’Exhibit 104 standard (données Inline XBRL). Cette divulgation indique un retour continu de capital aux actionnaires et peut intéresser les investisseurs axés sur le revenu.

Labcorp Holdings Inc. (NYSE: LH) hat gemäß Punkt 7.01 (Regulation FD) ein Formular 8-K eingereicht, um bekannt zu geben, dass der Vorstand eine Bardividende von 0,72 USD je Stammaktie beschlossen hat. Die Dividende wird am 11. September 2025 zahlbar sein für Aktionäre, die am Geschäftsschluss des 28. August 2025 im Aktienregister eingetragen sind. Weitere finanzielle Kennzahlen, strategische Initiativen oder Transaktionsdetails wurden in dieser Meldung nicht angegeben. Das Unternehmen stellte die zugehörige Pressemitteilung als Anlage 99.1 bereit und fügte die standardmäßige Anlage 104 (Inline XBRL-Cover-Daten) bei. Diese Offenlegung signalisiert fortgesetzte Kapitalrückflüsse an die Aktionäre und könnte für einkommensorientierte Investoren relevant sein.

Positive
  • Board declared a $0.72 cash dividend payable September 11, 2025 to shareholders of record August 28, 2025, reinforcing continued cash returns.
Negative
  • None.

Insights

TL;DR: Routine dividend declaration; signals ongoing capital return, impact modest.

The $0.72 per-share dividend aligns with Labcorp’s historical quarterly distribution pattern, indicating stable free cash flow and board commitment to shareholder returns. Because no change from prior payouts or special dividend premium is disclosed, the news is viewed as maintenance rather than a transformative catalyst. Income investors may welcome the confirmation of schedule and amount, but growth-oriented holders will find limited incremental insight.

TL;DR: Dividend confirmation supports yield stability; neutral on valuation.

A declared payout of $0.72 payable 9/11/25 provides visibility for dividend capture strategies and ex-dividend planning. However, without comparative yield data or guidance revisions, the announcement does not materially shift total-return expectations. Overall market impact is likely muted, keeping the disclosure in the neutral category.

Labcorp Holdings Inc. (NYSE: LH) ha presentato un Modulo 8-K ai sensi dell'Articolo 7.01 (Regolamento FD) per comunicare che il suo Consiglio di Amministrazione ha dichiarato un dividendo in contanti di 0,72 dollari per azione ordinaria. Il dividendo sarà pagabile l'11 settembre 2025 agli azionisti registrati alla chiusura delle attività del 28 agosto 2025. Non sono stati forniti altri dati finanziari, iniziative strategiche o dettagli sulle transazioni in questa comunicazione. La società ha allegato il comunicato stampa correlato come Allegato 99.1 e ha incluso il consueto Allegato 104 (dati Inline XBRL). Questa comunicazione indica un continuo ritorno di capitale agli azionisti e potrebbe essere rilevante per gli investitori orientati al reddito.

Labcorp Holdings Inc. (NYSE: LH) presentó un Formulario 8-K bajo el Ítem 7.01 (Regulación FD) para informar que su Junta Directiva ha declarado un dividendo en efectivo de 0,72 dólares por acción común. El dividendo será pagadero el 11 de septiembre de 2025 a los accionistas registrados al cierre del negocio el 28 de agosto de 2025. No se proporcionaron otros datos financieros, iniciativas estratégicas ni detalles de transacciones en esta presentación. La compañía adjuntó el comunicado de prensa correspondiente como Anexo 99.1 e incluyó el Anexo 104 estándar (datos Inline XBRL). Esta divulgación indica una continuidad en la devolución de capital a los accionistas y puede ser relevante para inversores enfocados en ingresos.

Labcorp Holdings Inc. (NYSE: LH)� 항목 7.01(규정 FD)� 따라 Form 8-K� 제출하여 이사회가 보통� 1주당 0.72달러� 현금 배당� 선언했다� 공시했습니다. 배당금은 2025� 9� 11일에 지�되며, 2025� 8� 28� 영업 종료 시점� 주주명부� 등재� 주주에게 지급됩니다. � 공시에서� 다른 재무 지�, 전략� 계획, 거래 세부사항은 제공되지 않았습니�. 회사� 관� 보도자료� 전시� 99.1� 제출했으� 표준 전시� 104(인라� XBRL 표지 데이�)� 포함했습니다. 이번 공시� 주주� 대� 지속적� 자본 환원� 의미하며, 수익 지� 투자자에� 중요� � 있습니다.

Labcorp Holdings Inc. (NYSE: LH) a déposé un formulaire 8-K en vertu de l'article 7.01 (Règlement FD) pour annoncer que son conseil d'administration a déclaré un dividende en espèces de 0,72 $ par action ordinaire. Le dividende sera payable le 11 septembre 2025 aux actionnaires inscrits à la clôture des opérations du 28 août 2025. Aucun autre indicateur financier, initiative stratégique ou détail transactionnel n’a été fourni dans ce dépôt. La société a joint le communiqué de presse associé en tant qu’Exhibit 99.1 et inclus l’Exhibit 104 standard (données Inline XBRL). Cette divulgation indique un retour continu de capital aux actionnaires et peut intéresser les investisseurs axés sur le revenu.

Labcorp Holdings Inc. (NYSE: LH) hat gemäß Punkt 7.01 (Regulation FD) ein Formular 8-K eingereicht, um bekannt zu geben, dass der Vorstand eine Bardividende von 0,72 USD je Stammaktie beschlossen hat. Die Dividende wird am 11. September 2025 zahlbar sein für Aktionäre, die am Geschäftsschluss des 28. August 2025 im Aktienregister eingetragen sind. Weitere finanzielle Kennzahlen, strategische Initiativen oder Transaktionsdetails wurden in dieser Meldung nicht angegeben. Das Unternehmen stellte die zugehörige Pressemitteilung als Anlage 99.1 bereit und fügte die standardmäßige Anlage 104 (Inline XBRL-Cover-Daten) bei. Diese Offenlegung signalisiert fortgesetzte Kapitalrückflüsse an die Aktionäre und könnte für einkommensorientierte Investoren relevant sein.

 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2025

Commission File Number: 001-40010

 

 

Pharvaris N.V.

(Translation of registrant’s name into English)

 

 

Emmy Noetherweg 2

2333 BK Leiden

The Netherlands

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

 

 
 


 

PHARVARIS N.V.

On July 10, 2025, Pharvaris N.V. issued a press release providing an update on the timing of the announcement of topline data from the RAPIDe-3 study. A copy of the press release is attached hereto as Exhibit 99.1 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act.

 

 

EXHIBIT INDEX

 

Exhibit No.

  

Description

99.1    Press Release, dated July 10, 2025.

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    PHARVARIS N.V.
Date: July 10, 2025     By:  

/s/ Berndt Modig

    Name:   Berndt Modig
    Title:   Chief Executive Officer

 

 

 

FAQ

What dividend did Labcorp (LH) announce in its July 2025 8-K?

Labcorp declared a $0.72 per-share cash dividend.

When is the record date for Labcorp’s $0.72 dividend?

The record date is August 28, 2025.

When will Labcorp pay the announced dividend?

Payment is scheduled for September 11, 2025.

Which exhibit contains the official dividend press release?

The press release is filed as Exhibit 99.1.

Does the 8-K include any earnings or transaction data?

No, the filing solely covers the dividend announcement and related exhibits.
Pharvaris N.V.

NASDAQ:PHVS

PHVS Rankings

PHVS Latest News

PHVS Latest SEC Filings

PHVS Stock Data

971.07M
34.61M
9.49%
89.48%
0.9%
Biotechnology
Healthcare
Netherlands
Leiden